IKENA ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.31 USD | +1.55% |
|
+3.97% | -33.50% |
| Mar. 12 | Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 12 | North American Morning Briefing : Inflation Data -2- | DJ |
Financials (USD)
| Sales 2024 * | 7M | Sales 2025 * | 10.8M | Capitalization | 62.25M |
|---|---|---|---|---|---|
| Net income 2024 * | -74M | Net income 2025 * | -80M | EV / Sales 2024 * | 8.89 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.76 x |
| P/E ratio 2024 * |
-0.83
x | P/E ratio 2025 * |
-0.85
x | Employees | 43 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.55% | ||
| 1 week | +3.97% | ||
| Current month | -7.75% | ||
| 1 month | -9.03% | ||
| 3 months | +1.55% | ||
| 6 months | -68.20% | ||
| Current year | -33.50% |
1 week
1.25
1.42
1 month
1.221.48
Current year
1.222.07
1 year
1.027.64
3 years
1.0226.49
5 years
1.0237.61
10 years
1.0237.61
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Manfredi
FOU | Founder | 53 | 16-01-31 |
Jotin Marango
DFI | Director of Finance/CFO | 45 | 22-04-24 |
Caroline Germa
CTO | Chief Tech/Sci/R&D Officer | 52 | Feb. 28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 16-02-29 | |
David Bonita
BRD | Director/Board Member | 48 | - |
| Director/Board Member | 55 | 20-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.29 | -4.44% | 154,017 |
| 24-04-23 | 1.35 | +3.85% | 263,930 |
| 24-04-22 | 1.3 | -2.26% | 239,341 |
| 24-04-19 | 1.33 | +5.56% | 334,007 |
| 24-04-18 | 1.26 | +1.61% | 184,615 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.29
USD
Average target price
8.333
USD
Spread / Average Target
+545.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.50% | 62.25M | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- IKNA Stock
